Solid Full Year Results
IQVIA achieved 5.5% revenue growth at constant currency excluding COVID revenue step down, adjusted diluted EPS growth over 9%, and free cash flow of $2.1 billion, representing a 41% increase.
Strong Operational Performance in Q4
Q4 revenue came in above the high end of guidance with about 4.5% growth excluding foreign exchange and COVID-related work. Adjusted diluted EPS grew nearly 10%, and the quarter achieved a record free cash flow.
Successful Strategic Renewals
IQVIA renewed all large pharma strategic partnerships, expanded existing partnerships, and secured new contracts, positioning the business for future growth.
Advancements in Global Health
IQVIA collaborated with organizations like the World Health Organization to control virus outbreaks, demonstrating its role as a key public health partner.
AI and Digital Innovations
Introduced 60 innovations in 2024, including 39 AI-enabled applications, and expanded digital business into Europe, doubling integrated websites and partners.
Biotech Funding and Pipeline Growth
Biotech funding exceeded $100 billion, a 44% increase from 2023, and the qualified pipeline showed positive growth across all segments.